PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy
Life Science Alliance · 2025
DOI: 10.26508/lsa.202402831 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Yiyang Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Cell Differentiation, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Protein Tyrosine Phosphatase, Non-Receptor Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stem Cell Network, Defeat Duchenne Canada, Canadian Government | Canadian Institutes of Health Research.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is a lethal disease caused by mutations in the DMD gene that encodes dystrophin. Dystrophin deficiency also impacts muscle stem cells (MuSCs), resulting in impaired asymmetric stem cell division and myogenic commitment. Using MuSCs from DMD patients and the DMD mouse model mdx , we found that PTPN1 phosphatase expression is up-regulated and STAT3 phosphorylation is concomitantly down-regulated in DMD MuSCs. To restore STAT3-mediated myogenic signaling, we examined the effect of K884, a novel PTPN1/2 inhibitor, on DMD MuSCs. Treatment with K884 enhanced STAT3 phosphorylation and promoted myogenic differentiation of DMD patient-derived MuSCs. In MuSCs from mdx mice, K884 treatment increased the number of asymmetric cell divisions, correlating with enhanced myogenic differentiation. Interestingly, the pro-myogenic effect of K884 is specific to human and murine DMD MuSCs and is absent from control MuSCs. Moreover, PTPN1/2 loss-of-function experiments indicate that the pro-myogenic impact of K884 is mediated mainly through PTPN1. We propose that PTPN1/2 inhibition may serve as a therapeutic strategy to restore the myogenic function of MuSCs in DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada.
- Goodman Cancer Institute, McGill University, Montréal, Canada.
- Department of Biochemistry, Faculty of Medicine and Health Sciences, McGill University, Montréal, Canada natasha.chang@mcgill.ca.
ORCID-Profile: Rebecca Robertson, Jules A Granet, Romina L Filippelli, Michel L Tremblay, Natasha C Chang
Förderung
- Stem Cell Network
- Defeat Duchenne Canada
- Canadian Government | Canadian Institutes of Health Research
- Richard and Edith Strauss Canada Foundation
- Aclon Foundation
Zitieren
APA
Liu, Y., Li, S., Robertson, R., Granet, J. A., Aubry, I., Filippelli, R. L., Tremblay, M. L., & Chang, N. C. (2025). PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy. Life Science Alliance. https://doi.org/10.26508/lsa.202402831
Vancouver
Liu Y, Li S, Robertson R, Granet JA, Aubry I, Filippelli RL, et al. PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy. Life Science Alliance. 2025. doi:10.26508/lsa.202402831
BibTeX
@article{Liu2025,
author = {Liu, Yiyang and Li, Shulei and Robertson, Rebecca and Granet, Jules A and Aubry, Isabelle and Filippelli, Romina L and Tremblay, Michel L and Chang, Natasha C},
title = {PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy},
journal = {Life Science Alliance},
year = {2025},
doi = {10.26508/lsa.202402831}
}
EUVIMED